UCB Clinical Trials: 517 Led Studies

Archive historyOct 2022 to Jun 2026

164 recorded changes across UCB trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 45 of these trials. One is shown below.

Completion date movePrimary completion moved 61 days laterNCT05077904 · recorded 1 Jun 2026

Track to read them

+160 more recorded changes · Track a drug to see every change the night it lands

Track bimekizumab

Most active programmes

The drugs appearing most often across UCB's recently active trials. Comparator arms are excluded.

Bimekizumab24 trials
Rozanolixizumab10 trials
Bimekizumab5 trials
Zilucoplan5 trials
Brivaracetam5 trials
zilucoplan (RA101495)3 trials

Upcoming readouts

Next primary completion dates among UCB's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Jul 2026A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of…Phase 3
Nov 2026ziMyG: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myastheni…Phase 2
Dec 2026A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents Wit…Phase 3
May 2027A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of…Phase 2
Dec 2027BeSeen: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplant…Phase 3
Apr 2028An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Stud…Phase 3

Top therapeutic areas

Conditions studied most often across UCB's recently active trials.

Generalized Myasthenia Gravis10 trials
Psoriatic Arthritis9 trials
Chronic Plaque Psoriasis8 trials
Epilepsy8 trials
Moderate to Severe Plaque Psoriasis6 trials
Moderate to Severe Chronic Plaque Psoriasis6 trials

UCB trials

The 50 most significant of UCB's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
RAISE-XTOpen-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisNCT04225871zilucoplan (RA101495)	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	200 est.	27 Jul 2026
BE HEARD EXTA Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaNCT04901195Bimekizumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	658 est.	28 Jul 2026
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresNCT05077904Staccato alprazolam	Phase 3	Locked · track to reveal	OngoingRecruiting	350 est.	31 Jul 2026
BE MOVINGA Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisNCT04436640Bimekizumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	508 est.	7 Aug 2026
roMyGA Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisNCT06149559rozanolixizumab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	12 est.	10 Aug 2026
EXPANDA Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyNCT04666610Brivaracetam	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	153 est.	24 Aug 2026
ziMyGA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisNCT06055959Zilucoplan	Phase 2	Locked · track to reveal	OngoingRecruiting	8 est.	16 Nov 2026
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study ParticipantsNCT07286682UCB5285	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	80 est.	13 Dec 2026
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaNCT06921850Bimekizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	40 est.	21 Dec 2026
BE UNIQUEA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisNCT06506916bimekizumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	89 est.	9 Mar 2027
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating WomenNCT06961747Zilucoplan	Phase 1	Locked · track to reveal	OngoingRecruiting	15 est.	23 Mar 2027
BE CARINGA Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)NCT06888193Bimekizumab	Phase 1	Locked · track to reveal	OngoingRecruiting	20 est.	3 May 2027
cosMOGA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)NCT05063162Rozanolixizumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	113 est.	6 May 2027
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisNCT07277660Galvokimig	Phase 2	Locked · track to reveal	OngoingRecruiting	160 est.	17 May 2027
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisNCT06540144rozanolixizumab	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	12 est.	17 Aug 2027
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisNCT07246564Rozanolixizumab	Phase 4	Locked · track to reveal	OngoingRecruiting	40 est.	15 Oct 2027
ziMyG+An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisNCT06435312Zilucoplan	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	8 est.	26 Oct 2027
GEMZA Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.NCT05064878Fenfluramine	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	87 est.	8 Nov 2027
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyNCT04658199UCB0107 (bepranemab)	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	19 est.	13 Dec 2027
BeSeenA Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisNCT07219420Bimekizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	320 est.	27 Dec 2027
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisNCT06668181Bimekizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	40 est.	12 Apr 2028
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsNCT07290036Bimekizumab regimen 1 iv	Phase 1	Locked · track to reveal	OngoingRecruiting	392 est.	18 May 2028
PHOENYCS FLYA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusNCT06617325DZP	Phase 3	Locked · track to reveal	OngoingRecruiting	450 est.	31 May 2028
BE TOGETHERA Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisNCT06425549bimekizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	168 est.	21 Aug 2028
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresNCT05076617Staccato alprazolam	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	300 est.	30 Nov 2028
MyVisionA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisNCT07463521Rozanolixizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	120 est.	1 Dec 2028
SPIRITSLC6A1-NDD Prospective Longitudinal Natural History StudyNCT07531511	—	Not yet scored	OngoingNot yet recruiting	60 est.	25 May 2029
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyNCT06315322Brivaracetam Film-coated tablet	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	70 est.	16 Nov 2029
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresNCT04715646Brivaracetam	Phase 3	Locked · track to reveal	OngoingRecruiting	70 est.	8 Jul 2030
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusNCT04976322Dapirolizumab pegol	Phase 3	Locked · track to reveal	OngoingEnrolling by invitation	760 est.	7 Aug 2030
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisNCT07465289Rozanolixizumab	Phase 3	Locked · track to reveal	OngoingNot yet recruiting	100 est.	23 Jan 2031
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese ParticipantsNCT06970301glovadalen	Phase 1	Locked · track to reveal	Completed	32 est.	29 May 2026
BE VITALA Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisNCT04009499Bimekizumab	Phase 3	Locked · track to reveal	Completed	1,131 est.	26 May 2026
CIMcareA Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisNCT04123795Certolizumab pegol	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	49 est.	9 Apr 2026
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisNCT06624228Bimekizumab	Phase 3	Locked · track to reveal	Completed	684 est.	6 Feb 2026
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy ParticipantsNCT07020988Staccato Alprazolam	Phase 1	Locked · track to reveal	Completed	55 est.	6 Jan 2026
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy ParticipantsNCT07220551UCB0022	Phase 1	Locked · track to reveal	Completed	14 est.	16 Dec 2025
A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy ParticipantsNCT06555601UCB3101	Phase 1	Locked · track to reveal	StoppedTerminated	56 est.	24 Nov 2025
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)NCT05277571UCB1381	Phase 1	Locked · track to reveal	Completed	109 est.	17 Jul 2025
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating WomenNCT06720714Rozanolixizumab	Phase 1	Locked · track to reveal	Completed	15 est.	12 May 2025
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut SyndromeNCT03936777ZX008 (Fenfluramine Hydrochloride)	Phase 3	Locked · track to reveal	Completed	412 est.	8 May 2025
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese ParticipantsNCT06716879Donzakimig	Phase 1	Locked · track to reveal	Completed	32 est.	4 Apr 2025
ATLANTISA Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseNCT06055985UCB0022	Phase 2	Locked · track to reveal	Completed	207 est.	31 Mar 2025
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyNCT05109234Brivaracetam Film-coated tablet	Phase 3	Locked · track to reveal	Completed	84 est.	18 Mar 2025
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's DiseaseNCT05543252Minzasolmin (UCB0599)	Phase 2	Locked · track to reveal	StoppedTerminated	428 est.	18 Mar 2025
BE CONNECTEDA Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasisNCT04718896bimekizumab	Phase 2	Locked · track to reveal	Completed	41 est.	12 Mar 2025
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide TreatmentNCT04627285Lacosamide	Phase 3	Locked · track to reveal	Completed	48 est.	12 Feb 2025
BE SHININGA Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque PsoriasisNCT06011733Bimekizumab	Phase 3	Locked · track to reveal	Completed	133 est.	5 Feb 2025
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisNCT06471361Zilucoplan	Phase 3	Locked · track to reveal	Completed	31 est.	28 Jan 2025
A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese ParticipantsNCT06315335UCB9741	Phase 1	Locked · track to reveal	Completed	40 est.	1 Jan 2025

View all trials517

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Phase 3RecruitingNCT05077904 ↗

Primary completion: Jul 2026; estimated
Enrollment: 350; estimated
Start: Dec 2021; UCB Biopharma SRL

Conditions

Stereotypical Prolonged Seizures

Interventions

Staccato alprazolam
Placebo

Brief summary

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Completion date move · 3

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

BE MOVING: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Phase 3Active, not recruitingNCT04436640 ↗

Primary completion: Aug 2026; estimated
Enrollment: 508; estimated
Start: Jun 2020; UCB Biopharma SRL

Conditions

Axial Spondyloarthritis
Ankylosing Spondylitis
r-axSpa
Nr-axSpa

Interventions

Bimekizumab

Brief summary

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Oct 2023

Enrollment change · 1

Status change · 1

Completion date move · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3Active, not recruitingNCT04666610 ↗

Primary completion: Aug 2026; estimated
Enrollment: 153; estimated
Start: Jul 2021; UCB Biopharma SRL

Conditions

Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions

Brivaracetam
Placebo

Brief summary

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2026

Completion date move · 3

Enrollment change · 1

Status change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

BE UNIQUE: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3Active, not recruitingNCT06506916 ↗

Primary completion: Mar 2027; estimated
Enrollment: 89; estimated
Start: Jul 2024; UCB Biopharma SRL

Conditions

Moderate to Severe Plaque Psoriasis
Psoriatic Arthritis

Interventions

bimekizumab

Brief summary

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

cosMOG: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

Phase 3Active, not recruitingNCT05063162 ↗

Primary completion: May 2027; estimated
Enrollment: 113; estimated
Start: Feb 2022; UCB Biopharma SRL

Conditions

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Interventions

Rozanolixizumab
Placebo

Brief summary

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3Enrolling by invitationNCT06540144 ↗

Primary completion: Aug 2027; estimated
Enrollment: 12; estimated
Start: Oct 2024; UCB Biopharma SRL

Conditions

Generalized Myasthenia Gravis

Interventions

rozanolixizumab

Brief summary

The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2025

Completion date move · 1

Status change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Phase 3RecruitingNCT06668181 ↗

Primary completion: Apr 2028; estimated
Enrollment: 40; estimated
Start: Mar 2025; UCB Biopharma SRL

Conditions

Enthesitis-related Arthritis
Juvenile Psoriatic Arthritis

Interventions

Bimekizumab

Brief summary

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2025

Completion date move · 1

Status change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3Active, not recruitingNCT06315322 ↗

Primary completion: Nov 2029; estimated
Enrollment: 70; estimated
Start: Jul 2024; UCB Biopharma SRL

Conditions

Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions

Brivaracetam Film-coated tablet
Brivaracetam oral solution

Brief summary

The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2024

Status change · 1

Completion date move · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

CIMcare: A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Phase 3Active, not recruitingNCT04123795 ↗

Primary completion: Apr 2026; actual
Enrollment: 49; estimated
Start: Jan 2020; UCB Biopharma SRL

Conditions

Moderate Chronic Plaque Psoriasis
Severe Chronic Plaque Psoriasis
Mixed Guttate/Plaque Psoriasis

Interventions

Certolizumab pegol
Placebo

Brief summary

The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 May 2026

Completion date move · 2

Enrollment change · 2

Status change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Phase 1CompletedNCT07020988 ↗

Primary completion: Jan 2026; actual
Enrollment: 55; estimated
Start: Jun 2025; UCB Biopharma SRL

Conditions

Healthy Participants

Interventions

Staccato Alprazolam
Midazolam
Diazepam

Brief summary

The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Mar 2026

Status change · 3

Completion date move · 1

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Phase 1CompletedNCT05277571 ↗

Primary completion: Jul 2025; actual
Enrollment: 109; estimated
Start: Mar 2022; UCB Biopharma SRL

Conditions

Atopic Dermatitis

Interventions

UCB1381
Placebo

Brief summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Nov 2025

Completion date move · 4

Status change · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Phase 3CompletedNCT03936777 ↗

Primary completion: May 2025; actual
Enrollment: 412; estimated
Start: Apr 2019; Zogenix, Inc.

Conditions

Dravet Syndrome
Lennox Gastaut Syndrome
Epileptic Encephalopathy

Interventions

ZX008 (Fenfluramine Hydrochloride)

Brief summary

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Jul 2025

Completion date move · 5

Status change · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

ATLANTIS: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Phase 2CompletedNCT06055985 ↗

Primary completion: Mar 2025; actual
Enrollment: 207; estimated
Start: Nov 2023; UCB Biopharma SRL

Conditions

Parkinson Disease

Interventions

Placebo
UCB0022

Brief summary

The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Jul 2025

Status change · 3

Completion date move · 3

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3CompletedNCT05109234 ↗

Primary completion: Mar 2025; actual
Enrollment: 84; estimated
Start: Mar 2022; UCB Biopharma SRL

Conditions

Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions

Brivaracetam Film-coated tablet
Brivaracetam oral solution

Brief summary

The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 Jul 2025

Completion date move · 7

Status change · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Phase 3CompletedNCT04627285 ↗

Primary completion: Feb 2025; actual
Enrollment: 48; estimated
Start: Dec 2020; UCB Biopharma SRL

Conditions

Epilepsy

Interventions

Lacosamide

Brief summary

The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Apr 2025

Completion date move · 3

Status change · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab

BE SHINING: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3CompletedNCT06011733 ↗

Primary completion: Feb 2025; actual
Enrollment: 133; estimated
Start: Oct 2023; UCB Biopharma SRL

Conditions

Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis

Interventions

Placebo
Bimekizumab

Brief summary

The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Apr 2025

Status change · 3

Completion date move · 2

Enrollment change · 1

Track UCB drugs to see every change the night it lands.

Track bimekizumab